Pathways of Serine and Glycine Metabolism in Primary Culture of Ovine Fetal Hepatocytes

Total Page:16

File Type:pdf, Size:1020Kb

Pathways of Serine and Glycine Metabolism in Primary Culture of Ovine Fetal Hepatocytes 003 1-3998/95/3805-0775$03.00/0 PEDIATRIC RESEARCH Vol. 38, No. 5, 1995 Copyright © 1995 International Pediatric Research Foundation, Inc. Printed ill U.S.A. Pathways of Serine and Glycine Metabolism in Primary Culture of Ovine Fetal Hepatocytes PATTI J. THUREEN, MICHAEL R. NARKEWICZ, FREDERICK C. BATTAGLIA, SUSAN TJOA, AND PAUL V. FENNESSEY Department of Pediatrics, Sections of Neonatology [P.J.T., F.C.B.], Gastroenterology, Hepatologyand Nutrition [M.R.N.], and Genetics [S.T., P.V.F.], University of Colorado Health Sciences Center, Denver, Colorado 80262 ABSTRACT Previous in vivo studies in the ovine fetus have demonstrated medium over 24 h, suggesting no reversibl e transamination of net serine production by the fetal liver, a pattern not seen in the glycine, and therefore no significant movement of glycine adult sheep. The goal of this study was to determine the major through the glyox alate pathw ay. These data demon strate that in metabolic pathways responsible for fetal hepatic serine produc­ primary culture offetal ovine hepatoctyes, approximately 30% of tion by using stable isotope methodology in primary culture of serine biosynthesis is derived from glycine, primarily via the late gestation ovine fetal hepatocytes. Specifically selected trac­ comb ined action of GCE and SHMT. (Pediatr Res 38: 775-782, ers of glycine were added to individual cultures, with production 1995) of labeled serine determin ed after 24 h of incubati on. When 13 13 [1- C ,lglycine or [2- C1]glycine was used as the initial tracer, serine enrichment at 24 h indic ated that approximately 30% of Abbreviations serine production comes from glycine. Quantitative comparison SHMT, serine hydroxymethyltransferase of serin e enrichment from these two tracers suggests that serine GCE, glycine cleavage enzyme system synthesis from glycine occurs via the combined action of the THF, tetrahydrofolate glycine cleavage enzyme system (GCE) and serine hydrox ym­ M, mass (atomic mass unit, amu) of the natural 12C or 14N 13 J5 ethyltransferase (SHMT). Using [1,2- C:z N1]glycine as the isomer of serine or glycine tracer, there was no significant increase in M+ 2 glycine in the MPE, mole percent enrichment During fetal life, amino acids are used for many functions late-ge station ovine fetal liver there is net hepatic uptake of such as precursors for protein synthesis and metabolic fuels, glycine with net hepatic release of serine (2, 7). In contrast, and for the synthesis of other carbon- and nitrogen- containing studies in the adult dog, cow, and rabbit have demonstrated a compounds including nucleic acids, glycogen, and lipid. There net hepatic uptake of both serine and glycine (5, 9-11). is increasing evidence that fetal amino acid metabolism has In the fetus, serine is important for nucleotide biosynthesis unique characteristics when compared with adult metabolism and as a potential donor of methyl carbon (12). The metabolic (1, 2). Some of these differences are due to ontologie changes precursors for fetal hepatic serine production are unknown. in organ-specific amino acid metabolism (3). In particular, Studies suggest that glucose in the fetal rat (4) and glycine in there appear to be differences in fetal hepatic serine metabo­ the fetal sheep (2) are significant precursors of fetal hepatic lism when compared with adult hepatic serine metabolism (2, serine biosynthesis. 4-8). In the sheep, in vivo studies have indicated that serine The enzymatic pathways by which glycine carbon could and glycin e have unique fetal metabolic characteristics com­ contribute to serine synthesis are shown in Figure 1 and may pared with those that have been demonstrated in adult animals include : 1) SHMT where glycine is combined with the donor of other species. Using the unique ability to chronically cath­ methyl group derived from a non-gl ycine source, 2) coupling eterize the ovine fetal liver, it has been demonstrated that in the of GeE with SHMT such that 2 glycine molecules are used to form 1 molecule of serine, or 3) by a more indirect pathway involving the transamination of glycine to glyoxalate and the Received March 14, 1995; accepted June 6, 1995. Correspondence and reprint requests: Patti J. Thureen, M.D., Section of Neonatology, eventual contribution of glycine carbon to methylene-THF. B-195, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, We have recently developed a system of primary culture of CO 80262. ovine fetal hepatocytes which maintains a pattern of net me­ Supported in part hy National Institutes of Health Grants HD29362-D I. 2P30 DK34914, IP30 HD27827, HDOI061-02, and HD27827-02. dium amino acid production and utilization similar to that seen 776 THURE EN £1' AL. 6 GLYCINE 2 X 10 cells/25-mm plate. Cells were incubated in humidified NH2 air/C0 2 (19:1) at 37°C and the medium was changed every I GCE 24 h. After adherence for 4-10 h, the medium was changed to ©H2-©OOH ©H2-THF + ©0 2 + NH3 standard medium (arginine-free minimal essential medium-a BA B A supplemented with 1.1 mM glucose, 2 mM lactate, 0.4 mM ornithine, 10 nM insulin, and antibiotics). The glucose and lactate levels were selected to approximate ovine fetal levels GLYCINE (14). NH2 I 1SHMT All aspects of animal care and use were reviewed and .QH2-.QOOH < approved by the institutional animal care and use committee. 2 1 Experimental design. In a typical experiment, after adher­ ence, hepatocytes were cultured in standard medium supple­ mented with the stable isotope of interest at a 10-15% target r enrichment. The medium was sampled at 0 and 24 h, and then ©H2-THF analyzed for amino acid concentration and enrichment as B outlined below. Preliminary data demonstrated linear changes in both MPE and serine/glycine concentration changes over time. For determination of serine to glycine interconversion, ©H2-©OO + NH4+ [l-13Cd serine was used as the tracer. For assessment of gly­ BA cine to serine in tercon version , [1- 13Cdglycine and GLYOXALATE [2-13Cd glycine were used as the tracers. These two stable Figure 1. Metabolic pathways of serine and glycine interconversion. Possible pathways of serine production from glycine and the source of the different isotopes allow the determination of the contribution of the serine carbons when serine is produced from glycine. The 3 carbon (or the "B" combined action ("coupling") of GCE and SHMT to the IO car bon) of serine is prov ided by the intermed iate CH2-THF (tvS,N ­ biosynthesis of serine from glycine compared with the contri­ methylene-tetrahydrofolic acid) which is produced from glycine by the action bution of SHMT alone. The degree of coupling of these two of GCE . An alternative way of contributing the "B" carbon to the one-carbon pool is via Iransamination of glycin e to glyoxalate with eventual production of enzymes was expressed as the ratio of the 24-h serine M+1 MPE fro m [2- 13C ycine/24-h serine MPE from CH2-THF. Serin e carbons 1 and 2 come directly from glycine, which combi nes 1]gl 13 with CH2-THF via the enzyme SHMT. [l- Cd glycine. A ratio = 1 indicates the absence of coupling, whereas a ratio = 2 suggests complete coupling of these GCE and SHMT. For further evidence supporting or refuting cou­ pling of GCE and SHMT, and to investigate the contribution of across the fetal ovine liver in vivo (13). Specifically, there is a the glyoxalate pathway to serine biosynthesis, studies were net production of serine and a net uptake of glycine. The aims 13 13C 15Nd performed with [1,2- C2] glycine, [2- l glycine, and of this study were: 1) to compare stable isotope studies of 13 15N serine biosynthesis in primary culture of fetal ovine hepato­ [1,2- C2 d glycine. cytes with our previous in vivo studies, and 2) to identify the Changes in medium serine and glycine concentrations over relative contribution of the specific pathways (i.e. GCE, 24 h were studied in parallel cultures to which no serine or SHMT, and glyoxalate pathways) by which glycine is con­ glycine isotopes had been added. The number of replicate verted to serine in primary fetal ovine hepatocytes using this cultures per isotope per animal ranged from 2 to 11 (mean of tracer methodology. 4). Medium was harvested by aspirating with a sterile pipette at the indicated times, followed by centrifugation (10,000 X g, 30 s at 4°C) and then the medium was snap frozen for subsequent METHODS analysis. As a control, medium was incubated without cells for Cell isolation and primary culture of hepatocytes. Colum­ 24 h and analyzed in a similar manner. bia-Rambouillet pregnant ewes were anesthetized with pento­ To determine the effect of medium serine concentration on barbital (25 mg/kg i.v.). The fetus was delivered by cesarean hepatocyte serine production, experiments were performed section, anesthetized with pentobarbital (20 rug/kg), and hep­ under normal medium conditions (serine concentration approx­ arinized (1000 U/kg of body weight). Hepatocytes were iso­ imately 0.24 }..LmollmL) and compared with medium conditions lated from these late gestation fetal lambs by in situ perfusion where the serine concentration was approximately 3.5 times and collagenase digestion as previously reported (13). Cell the normal level (serine approximately 0.79 }..LmollmL). viability was assessed by trypan blue exclusion. Only cell For most of the results, a sampling time of 24 h was selected isolations with > 92% viable cells were used for primary for the following reasons: 1) Initial cultures with multiple time culture. After isolation, cells were resuspended in seeding points over
Recommended publications
  • The Role of Agmatine and Arginine Decarboxylase in Ischemic Tolerance After Transient Cerebral Ischemia in Rat Models
    The role of agmatine and arginine decarboxylase in ischemic tolerance after transient cerebral ischemia in rat models Jin Young Jung Department of Medicine The Graduate School, Yonsei University The role of agmatine and arginine decarboxylase in ischemic tolerance after transient cerebral ischemia in rat models Directed by Professor Seung Kon Huh The Doctoral Dissertation submitted to the Department of Medicine, the Graduate School of Yonsei University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Jin Young Jung May 2007 This certifies that the Doctoral Dissertation of Jin Young Jung is approved. __________________________________ Thesis Supervisor: Seung Kon Huh __________________________________ Jong Eun Lee: Thesis Committee Member #1 __________________________________ Jin Woo Chang: Thesis Committee Member #2 __________________________________ Duck Sun Ahn: Thesis Committee Member #3 __________________________________ Ji Cheol Shin: Thesis Committee Member #4 The Graduate School Yonsei University May 2007 Acknowledgements Some may consider this short section of the thesis trivial but for me it is a chance to express my sincerest gratitude to those that I am truly thankful. First of all, I would like to express my deepest gratitude to my thesis supervisor and mentor Professor Seung Kon Huh. He has inspired me when I was troubled and always gave me a warm heart. I would also like to thank Professor Jong Eun Lee who shared her valuable time on the execution and interpretation of this study, Professor Jin Woo Chang who always inspiring me with passion and discerning insight. Professor Duck Sun Ahn whose insightful comments were essential in completing this thesis, Professor Ji Cheol Shin for the excellent suggestion for improvement in this thesis.
    [Show full text]
  • Targeting Glycine Reuptake in Alcohol Seeking and Relapse
    JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. TITLE PAGE Targeting Glycine Reuptake in Alcohol Seeking and Relapse Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov, Rainer Spanagel Downloaded from The primary laboratory of origin: Institute of Psychopharmacology, Central Institute of jpet.aspetjournals.org Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; at ASPET Journals on September 30, 2021 VV, MR, TTT, RS: Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; DA: Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland; BB, AB: Department of Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; AB: Department of Psychopharmacology, Pavlov Medical University, St Petersburg, Russia JPET #244822 JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. RUNNING TITLE GlyT1 in Alcohol Seeking and Relapse Corresponding author with complete address: Valentina Vengeliene, Institute of Psychopharmacology, Central Institute of Mental Health (CIMH), J5, 68159 Mannheim, Germany Email: [email protected], phone: +49-621-17036261; fax: +49-621- Downloaded from 17036255 jpet.aspetjournals.org The number of text pages: 33 Number of tables: 0 Number of figures: 6 Number of references: 44 at ASPET Journals on September 30, 2021 Number of words in the Abstract: 153 Number of words in the Introduction: 729 Number of words in the Discussion: 999 A recommended section assignment to guide the listing in the table of content: Drug Discovery and Translational Medicine 2 JPET #244822 JPET Fast Forward.
    [Show full text]
  • Amino Acid Chemistry
    Handout 4 Amino Acid and Protein Chemistry ANSC 619 PHYSIOLOGICAL CHEMISTRY OF LIVESTOCK SPECIES Amino Acid Chemistry I. Chemistry of amino acids A. General amino acid structure + HN3- 1. All amino acids are carboxylic acids, i.e., they have a –COOH group at the #1 carbon. 2. All amino acids contain an amino group at the #2 carbon (may amino acids have a second amino group). 3. All amino acids are zwitterions – they contain both positive and negative charges at physiological pH. II. Essential and nonessential amino acids A. Nonessential amino acids: can make the carbon skeleton 1. From glycolysis. 2. From the TCA cycle. B. Nonessential if it can be made from an essential amino acid. 1. Amino acid "sparing". 2. May still be essential under some conditions. C. Essential amino acids 1. Branched chain amino acids (isoleucine, leucine and valine) 2. Lysine 3. Methionine 4. Phenyalanine 5. Threonine 6. Tryptophan 1 Handout 4 Amino Acid and Protein Chemistry D. Essential during rapid growth or for optimal health 1. Arginine 2. Histidine E. Nonessential amino acids 1. Alanine (from pyruvate) 2. Aspartate, asparagine (from oxaloacetate) 3. Cysteine (from serine and methionine) 4. Glutamate, glutamine (from α-ketoglutarate) 5. Glycine (from serine) 6. Proline (from glutamate) 7. Serine (from 3-phosphoglycerate) 8. Tyrosine (from phenylalanine) E. Nonessential and not required for protein synthesis 1. Hydroxyproline (made postranslationally from proline) 2. Hydroxylysine (made postranslationally from lysine) III. Acidic, basic, polar, and hydrophobic amino acids A. Acidic amino acids: amino acids that can donate a hydrogen ion (proton) and thereby decrease pH in an aqueous solution 1.
    [Show full text]
  • Insights Into the Mn Binding Site in the Agmatinase-Like Protein (ALP): A
    International Journal of Molecular Sciences Article Insights into the Mn2+ Binding Site in the Agmatinase-Like Protein (ALP): A Critical Enzyme for the Regulation of Agmatine Levels in Mammals María-Belen Reyes 1, José Martínez-Oyanedel 1,*, Camila Navarrete 1, Erika Mardones 1, Ignacio Martínez 1,Mónica Salas 2, Vasthi López 3, María García-Robles 4, Estefania Tarifeño-Saldivia 1, Maximiliano Figueroa 1, David García 1 and Elena Uribe 1,* 1 Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad de Concepción, Casilla 160-C, Concepción 4070386, Chile; [email protected] (M.-B.R.); [email protected] (C.N.); [email protected] (E.M.); [email protected] (I.M.); [email protected] (E.T.-S.); [email protected] (M.F.); [email protected] (D.G.) 2 Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia 5110566, Chile; [email protected] 3 Departamento de Ciencias Biomédicas, Universidad Católica del Norte, Coquimbo 1781421, Chile; [email protected] 4 Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Casilla 160-C, Concepción 3349001, Chile; [email protected] * Correspondence: [email protected] (J.M.-O.); [email protected] (E.U.) Received: 28 April 2020; Accepted: 5 June 2020; Published: 10 June 2020 Abstract: Agmatine is a neurotransmitter with anticonvulsant, anti-neurotoxic and antidepressant-like effects, in addition it has hypoglycemic actions. Agmatine is converted to putrescine and urea by agmatinase (AGM) and by an agmatinase-like protein (ALP), a new type of enzyme which is present in human and rodent brain tissues. Recombinant rat brain ALP is the only mammalian protein that exhibits significant agmatinase activity in vitro and generates putrescine under in vivo conditions.
    [Show full text]
  • Solutions to 7.012 Problem Set 1
    MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel Solutions to 7.012 Problem Set 1 Question 1 Bob, a student taking 7.012, looks at a long-standing puddle outside his dorm window. Curious as to what was growing in the cloudy water, he takes a sample to his TA, Brad Student. He wanted to know whether the organisms in the sample were prokaryotic or eukaryotic. a) Give an example of a prokaryotic and a eukaryotic organism. Prokaryotic: Eukaryotic: All bacteria Yeast, fungi, any animial or plant b) Using a light microscope, how could he tell the difference between a prokaryotic organism and a eukaryotic one? The resolution of the light microscope would allow you to see if the cell had a true nucleus or organelles. A cell with a true nucleus and organelles would be eukaryotic. You could also determine size, but that may not be sufficient to establish whether a cell is prokaryotic or eukaryotic. c) What additional differences exist between prokaryotic and eukaryotic organisms? Any answer from above also fine here. In addition, prokaryotic and eukaryotic organisms differ at the DNA level. Eukaryotes have more complex genomes than prokaryotes do. Question 2 A new startup company hires you to help with their product development. Your task is to find a protein that interacts with a polysaccharide. a) You find a large protein that has a single binding site for the polysaccharide cellulose. Which amino acids might you expect to find in the binding pocket of the protein? What is the strongest type of interaction possible between these amino acids and the cellulose? Cellulose is a polymer of glucose and as such has many free hydroxyl groups.
    [Show full text]
  • Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors
    Neurochemical Research (2019) 44:735–750 https://doi.org/10.1007/s11064-018-02712-1 REVIEW PAPER Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors Sumit Barua1 · Jong Youl Kim1 · Jae Young Kim1 · Jae Hwan Kim4 · Jong Eun Lee1,2,3 Received: 15 October 2018 / Revised: 19 December 2018 / Accepted: 24 December 2018 / Published online: 4 January 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The central nervous system (CNS) is the most injury-prone part of the mammalian body. Any acute or chronic, central or peripheral neurological disorder is related to abnormal biochemical and electrical signals in the brain cells. As a result, ion channels and receptors that are abundant in the nervous system and control the electrical and biochemical environment of the CNS play a vital role in neurological disease. The N-methyl-D-aspartate receptor, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid receptor, kainate receptor, acetylcholine receptor, serotonin receptor, α2-adrenoreceptor, and acid-sensing ion channels are among the major channels and receptors known to be key components of pathophysiological events in the CNS. The primary amine agmatine, a neuromodulator synthesized in the brain by decarboxylation of L-arginine, can regu- late ion channel cascades and receptors that are related to the major CNS disorders. In our previous studies, we established that agmatine was related to the regulation of cell differentiation, nitric oxide synthesis, and murine brain endothelial cell migration, relief of chronic pain, cerebral edema, and apoptotic cell death in experimental CNS disorders.
    [Show full text]
  • Flavor Masking/Enhancement
    T,&YJJIVMRK %RMQEP*IIHW *PEZSV1EWOMRK)RLERGIQIRX 'LIQMGEP-RXIVQIHMEXI ® §%7MQTPI%QMRS%GMH [MXL'SQTPI\*YRGXMSREPMX] Glycine, also known as aminoacetic acid, is the simplest amino acid. Found naturally in many foods, glycine is also synthesized in the human body, where, among other functions, it helps improve glycogen storage, is utilized in the synthesis of hemoglobin, collagen, and glutathione, and facilitates the amelioration of high blood fat and uric acid levels. In addition to the important metabolic functions glycine &YJJIVMRKT,7XEFMPM^EXMSR performs, this versatile substance is widely used in With acidic and basic properties in the same molecule, a range of applications, such as flavor enhancers and glycine acts to buffer or stabilize the pH of those maskers, pH buffers and stabilizers, ingredients in phar- systems containing it. Many of the uses for glycine maceutical products, and as a chemical intermediate. depend on this ability. Glycine’s efficiency in stabilizing pH has resulted in %X,SQIMRE,SWXSJ%TTPMGEXMSRW its wide usage as a buffering agent in many pharma- ceutical products. Antacid and analgesic products are often formulated with glycine to stabilize the acidity *PEZSV1EWOMRK*PEZSV)RLERGIQIRX of the digestive tract and prevent hyperacidity. Glycine Glycine has a refreshingly sweet taste, and is one and a has been shown to promote the gastric absorption of half times as sweet as sugar. In addition to its sweetness, certain drugs, including aspirin. glycine also has the ability to mellow saltiness and bit- terness. The bitter after-taste of saccharin, for example, When formulated in an aluminum-zirconium is masked by glycine. Carbonated soft drinks and flavor tetrachlorohydrex complex, glycine buffers the high concentrates based on saccharin may contain up to 0.2 acidity of active ingredients in antiperspirants.
    [Show full text]
  • Toluene Toxicity
    Case Studies in Environmental Medicine Course: SS3061 Date: February 2001 Original Date: August 1993 Expiration Date: February 28, 2007 TOLUENE TOXICITY Environmental Alert Use of toluene is increasing, in part because of its popularity as a solvent replacement for benzene. Gasoline contains 5% to 7% toluene by weight, making toluene a common airborne contaminant in industrialized countries. Many organic solvents have great addictive potential; toluene is the most commonly abused hydrocarbon solvent, primarily through “glue sniffing.” This monograph is one in a series of self- instructional publications designed to increase the primary care provider’s knowledge of hazardous substances in the environment and to aid in the evaluation of potentially exposed patients. This course is also available on the ATSDR Web site, www.atsdr.cdc.gov/HEC/CSEM/. See page 3 for more information about continuing medical education credits, continuing nursing education units, and continuing education units. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry Division of Toxicology and Environmental Medicine Toluene Toxicity Table of Contents ATSDR/DHEP Authors: Kim Gehle, MD, MPH; Felicia Pharagood-Wade, MD; Darlene Case Study ......................................................................................... 5 Johnson, RN, BSN, MA; Lourdes Who’s At Risk .................................................................................... 5 Rosales-Guevara, MD ATSDR/DHEP Revision Planners: Exposure Pathways ...........................................................................
    [Show full text]
  • Effects of Glycine on Collagen, PDGF, and EGF Expression in Model of Oral Mucositis
    nutrients Article Effects of Glycine on Collagen, PDGF, and EGF Expression in Model of Oral Mucositis Odara Maria de Sousa Sá 1,* , Nilza Nelly Fontana Lopes 2, Maria Teresa Seixas Alves 3 and Eliana Maria Monteiro Caran 4 1 Department of Pediatrics, Federal University of São Paulo, São Paulo 04023-062, Brazil 2 Former Head Division of Dentistry, Pediatric Oncology Institute, São Paulo 04023-062, Brazil; nnfl[email protected] 3 Department of Pathology, Federal University of São Paulo, São Paulo 04023-062, Brazil; [email protected] 4 Department of Pediatrics, IOP/GRAACC Medical School of Federal University of São Paulo, São Paulo 04023-062, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-086-99932-5493 Received: 10 July 2018; Accepted: 5 September 2018; Published: 12 October 2018 Abstract: Oral mucositis is frequently a toxic effect of chemotherapeutic and/or radiotherapeutic treatment, resulting from complex multifaceted biological events involving DNA damage. The clinical manifestations have a negative impact on the life quality of cancer patients. Preventive measures and curative treatment of mucositis are still not well established. The glycine has anti-inflammatory, immunomodulatory, and cytoprotective actions, being a potential therapeutic in mucositis. The objective was to evaluate the effects of glycine on the expression of collagen and growth factors, platelet and epidermal in a hamster model oral mucositis. The mucositis was induced by the protocol of Sonis. There were 40 hamsters used, divided into two groups: Group I-control; Group II-supplemented with 5% intraperitoneal glycine, 2.0 mg/g diluted in hepes. Histopathological sections were used to perform the immune-histochemical method, the evaluation of collagen expression, and the growth factors: Epidermal growth factor (EGF) and platelet (PDGF).
    [Show full text]
  • Proposal of the Annotation of Phosphorylated Amino Acids and Peptides Using Biological and Chemical Codes
    molecules Article Proposal of the Annotation of Phosphorylated Amino Acids and Peptides Using Biological and Chemical Codes Piotr Minkiewicz * , Małgorzata Darewicz , Anna Iwaniak and Marta Turło Department of Food Biochemistry, University of Warmia and Mazury in Olsztyn, Plac Cieszy´nski1, 10-726 Olsztyn-Kortowo, Poland; [email protected] (M.D.); [email protected] (A.I.); [email protected] (M.T.) * Correspondence: [email protected]; Tel.: +48-89-523-3715 Abstract: Phosphorylation represents one of the most important modifications of amino acids, peptides, and proteins. By modifying the latter, it is useful in improving the functional properties of foods. Although all these substances are broadly annotated in internet databases, there is no unified code for their annotation. The present publication aims to describe a simple code for the annotation of phosphopeptide sequences. The proposed code describes the location of phosphate residues in amino acid side chains (including new rules of atom numbering in amino acids) and the diversity of phosphate residues (e.g., di- and triphosphate residues and phosphate amidation). This article also includes translating the proposed biological code into SMILES, being the most commonly used chemical code. Finally, it discusses possible errors associated with applying the proposed code and in the resulting SMILES representations of phosphopeptides. The proposed code can be extended to describe other modifications in the future. Keywords: amino acids; peptides; phosphorylation; phosphate groups; databases; code; bioinformatics; cheminformatics; SMILES Citation: Minkiewicz, P.; Darewicz, M.; Iwaniak, A.; Turło, M. Proposal of the Annotation of Phosphorylated Amino Acids and Peptides Using 1. Introduction Biological and Chemical Codes.
    [Show full text]
  • Nebraska Medicaid Program Monthly Maximum Allowable Cost (MAC) Listing
    1 ** Confidential and Proprietary ** Septemb 2021 Nebraska Medicaid Program Monthly Maximum Allowable Cost (MAC) Listing Due to frequent changes in price and product availability, this listing should NOT be considered all-inclusive. Updated listings will be posted monthly. Effective MAC Generic Name Strength Form Route Date Price 0.9 % SODIUM CHLORIDE 0.9 % VIAL INJECTION 01/27/2021 0.07271 0.9 % SODIUM CHLORIDE 0.9 % IV SOLN INTRAVEN 03/17/2021 0.00327 ABACAVIR SULFATE 20 MG/ML SOLUTION ORAL 12/30/2020 0.67190 ABACAVIR SULFATE 300 MG TABLET ORAL 06/09/2021 0.89065 ABACAVIR SULFATE/LAMIVUDINE 600-300MG TABLET ORAL 03/10/2021 2.11005 ABACAVIR/LAMIVUDINE/ZIDOVUDINE 150-300 MG TABLET ORAL 12/11/2019 26.74276 ABIRATERONE ACETATE 250 MG TABLET ORAL 09/29/2019 11.03425 ABIRATERONE ACETATE 500 MG TABLET ORAL 01/12/2021 145.40750 ACACIA POWDER MISCELL 01/22/2020 0.14149 ACAMPROSATE CALCIUM 333 MG TABLET DR ORAL 07/29/2020 0.97128 ACARBOSE 100 MG TABLET ORAL 09/08/2021 0.40079 ACARBOSE 50 MG TABLET ORAL 11/11/2020 0.28140 ACARBOSE 25 MG TABLET ORAL 01/13/2021 0.22780 ACEBUTOLOL HCL 200 MG CAPSULE ORAL 09/08/2021 0.88574 ACEBUTOLOL HCL 400 MG CAPSULE ORAL 03/31/2021 1.02443 ACESULFAME POTASSIUM 100 % POWDER MISCELL 01/22/2020 2.98320 ACETAMINOPHEN 500 MG CAPSULE ORAL 06/03/2020 0.04047 ACETAMINOPHEN 160 MG/5ML ORAL SUSP ORAL 08/18/2021 0.02010 ACETAMINOPHEN 160 MG/5ML ORAL SUSP ORAL 06/16/2021 0.16884 ACETAMINOPHEN 160 MG/5ML SOLUTION ORAL 08/04/2021 0.30514 ACETAMINOPHEN 325/10.15 SOLUTION ORAL 08/04/2021 0.17266 NE MAC Pricing Information contained in this document is confidential and proprietary and is available to you solely for the purpose of assisting with claim processing and program reimbursement analysis.
    [Show full text]
  • A Pilot Open-Label Trial of Use of the Glycine Transporter I Inhibitor
    nal atio Me sl d n ic a in r e T Yang, et al., Transl Med (Sunnyvale) 2014, 4:2 Translational Medicine DOI: 10.4172/2161-1025.1000127 ISSN: 2161-1025 Research Article Open Access A Pilot Open-Label Trial of Use of the Glycine Transporter I Inhibitor, Sarcosine, in High-Functioning Children with Autistic Disorder Pinchen Yang1, Hsien-Yuan Lane2, Cheng-Fang Yen1, Chen-Lin Chang 3,4* 1Department of Psychiatry, College of Medicine, Kaohsiung Medical University and Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2Institute of Clinical Medical Science & Departments of Psychiatry, China Medical University and Hospital, Taichung, Taiwan 3Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University and Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 4Department of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan *Corresponding author: Chen-Lin Chang, 100, Shin Chuan 1 st Rd, Kaohsiung 807, Taiwan, Graduate Institute of Medicine, Kaohsiung Medical University and Kaohsiung Medical University Hospital & Department of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, Tel:+886-9-36360220; Fax: +886-7-3134761; E-mail: [email protected] Rec date: Apr 01, 2014; Acc date: Apr 17, 2014; Pub date: Apr 22, 2014 Copyright: © 2014 Yang P et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract This open-label trial examined the efficacy and safety of a glycine transporter I inhibitor, sarcosine, in the 24-week treatment of high-functioning children with autistic disorder.
    [Show full text]